Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer

Cancer Statistics, 2008

2008 • 10,165 citations

p53 Mutations in Human Cancers

1991 • 8,133 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

The Central Role of CD4+ T Cells in the Antitumor Immune Response

1998 • 1,332 citations

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1991 • 619 citations

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

2008 • 550 citations

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

2006 • 428 citations

Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides

2002 • 410 citations

The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment

2005 • 364 citations

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

2008 • 360 citations

Transient regulatory T-cells: A state attained by all activated human T-cells

2006 • 336 citations

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

2004 • 311 citations

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

2008 • 300 citations

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

1993 • 267 citations

Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes

1997 • 264 citations

CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity

2007 • 254 citations

Association of cervical cancer with the presence of CD4⁺regulatory T cells specific for human papillomavirus antigens

2007 • 215 citations

Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation

2008 • 197 citations

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication

2004 • 171 citations

Prognostic Value of Tumor-Infiltrating Dendritic Cells in Colorectal Cancer: Role of Maturation Status and Intratumoral Localization

2005 • 164 citations

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine

2002 • 162 citations

Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide

1996 • 155 citations

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

2006 • 114 citations

The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire

2000 • 110 citations

Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model

2005 • 108 citations

Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma

2001 • 108 citations

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes

2002 • 107 citations

Vaccination with p53-peptide?pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

2004 • 107 citations

Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer

1995 • 98 citations

Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.

2002 • 97 citations

Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.

1999 • 94 citations

Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

2002 • 91 citations

Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation

2007 • 77 citations

Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)

2008 • 75 citations

Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms

1998 • 60 citations

Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer

2001 • 60 citations

Cytotoxic T‐Lymphocyte Clones, Established by Stimulation with the HLA‐A2 Binding p53_65–73 Wild Type Peptide Loaded on Dendritic Cells In Vitro, Specifically Recognize and Lyse HLA‐A2 Tumour Cells Overexpressing the p53 Protein

2000 • 57 citations

Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

2002 • 57 citations

p53: A Potential Target Antigen for Immunotherapy of Cancer

2000 • 57 citations

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man

2002 • 56 citations

Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen

2008 • 54 citations

Clinical impact of HLA class I expression in rectal cancer

2007 • 51 citations

CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen

2001 • 50 citations

Unique tumor antigens redefined as mutant tumor-specific antigens

1996 • 49 citations

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

2003 • 48 citations

Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia

2008 • 37 citations

Immunologic aspect of ovarian cancer and p53 as tumor antigen

2005 • 34 citations

P53‐specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy

2007 • 34 citations

Magnitude and polarization of P53‐specific T‐helper immunity in connection to leukocyte infiltration of colorectal tumors

2003 • 28 citations

p53 and HLA class-I expression are not down-regulated in colorectal cancer liver metastases

2004 • 23 citations

Immunotherapy of cancer through targeting of the p53 tumor antigen.

2002 • 7 citations